ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study

OBJECTIVE: Tumor necrosis factor (TNF) and interleukin‐17A (IL‐17A) may independently contribute to the pathophysiology of rheumatoid arthritis (RA). This study sought to evaluate the safety and efficacy of ABT‐122, a novel dual variable domain immunoglobulin targeting human TNF and IL‐17A, in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Weinblatt, Michael E., Aelion, Jacob A., Mansikka, Heikki T., Peloso, Paul M., Chen, Kun, Li, Yihan, Othman, Ahmed A., Khatri, Amit, Khan, Nasser S., Padley, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704363/
https://www.ncbi.nlm.nih.gov/pubmed/29855172
http://dx.doi.org/10.1002/art.40580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704363/
https://www.ncbi.nlm.nih.gov/pubmed/29855172
http://dx.doi.org/10.1002/art.40580

Ejemplares similares